Isofol adds new trial sites to boost recruitment in arfolitixorin colorectal cancer study

• Isofol expanded its phase Ib/II colorectal cancer trial for arfolitixorin by adding new clinical sites to speed patient recruitment.
• No trial results were presented; the move targets faster enrollment to keep the program on track to enter phase II before year-end.
• Essen University Hospital will start enrolling patients during phase Ib; another German university hospital is being prepared to join.
• Phase II is planned across 10-15 sites in Germany, other European countries, with parallel recruitment in Japan via a bridging study.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Isofol Medical AB published the original content used to generate this news brief on August 24, 2026, and is solely responsible for the information contained therein.